Adjusted daily closes · 252 observations · as of Nov 6, 2026
Historical data, not a forecast
1 month
+6.6%
3 months
+11.1%
6 months
+28.9%
1 year
+23.3%
Year to date
+20.5%
52-week range
$283.32 – $480.07
Fundamental snapshot
Latest reported period: Jul 4, 2026
Sharadar reported data
Market cap
$44.96B
P/E
270.6
P/B
3
P/S
9.7
Revenue
$4.64B
Net income
$166.14M
Diluted EPS
4
Gross margin
50.90%
Net margin
3.60%
Return on equity
1.90%
Total debt
$5.45B
Cash
$539M
Free cash flow
$401.29M
Latest eight reported quarters
Reported quarterly values, newest first
Period
Revenue
Net income
Gross margin
Net margin
Free cash flow
Jul 4, 2026
$1.65B
-$136M
44.60%
-8.30%
$153M
Apr 4, 2026
$1.27B
-$72M
46.40%
-5.70%
-$42M
Dec 31, 2025
$932.36M
$225.21M
61.10%
24.20%
$128.42M
Sep 27, 2025
$799.89M
$148.92M
59.00%
18.60%
$161.87M
Jun 28, 2025
$771.33M
$147.11M
58.30%
19.10%
$18.55M
Mar 29, 2025
$661.71M
$121.38M
58.20%
18.30%
$233.81M
Dec 31, 2024
$872.71M
$231.4M
60.10%
26.50%
$188.04M
Sep 28, 2024
$740.31M
$161.5M
59.30%
21.80%
$178.96M
Reported figures can reflect company reporting conventions, restatements, or sector-specific accounting. Verify against filings before relying on a valuation comparison.
Revvity, Inc. (NYSE:RVTY) recently surpassed analyst expectations for its quarterly report, with revenues reaching US$710m and statutory earnings per share outperforming by 13%. Despite these strong results, analysts have made no significant changes to their 2027 revenue and EPS forecasts, which remain at US$3.03b and US$2.86 respectively, and the consensus price target held steady at US$150. While Revvity's future growth is expected to improve compared to its past performance, it is still projected to lag behind the broader industry's revenue growth.
Agilent Technologies recently launched its 5987A single quadrupole mass selective detector with GC Assist and MassHunter 14, which integrates with their 8890B and 8860B gas chromatographs to improve lab efficiency, automation, and energy consumption. This launch aligns with Agilent's strategy to deliver high-end lab hardware, software, and services for steadier, higher-margin cash flows, especially by focusing on software and data-heavy workflows. While the new GC/MS system supports the investment narrative, risks include pressure on research budgets and integration complexity for advanced instruments and software.
You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load.Many donated money to President Trump’s favored causes and became...